Tests combined radiation treatment for high risk prostate cancer
Tests a combined radiotherapy approach in adults with high risk prostate cancer.
Plain-language title generated from the registry record
Registry title: Towards Optimal Treatment for High Risk Prostate Cancer
Key facts
- Where
- Leidschendam, NetherlandsSee the site
Where in Netherlands
- Haaglanden Medical CentreLeidschendam, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Haaglanden Medical Centre
- Trial code
- NCT06204341
- Record updated
- 19 September 2024
- Original description
The goal of this clinical trial is to combine several optimized treatments of high risk prostate cancer. The main question to answer is: is it safe to combine these optimized treatments.Read full original descriptionShow less
Towards Optimal Treatment for High Risk Prostate Cancer; Stereotactic Pelvic Radiotherapy with Focal Boost to the Primary Tumour
The goal of this clinical trial is to combine several optimized treatments of high risk prostate cancer. The main question to answer is: is it safe to combine these optimized treatments.
* patients will be irradiated on the prostate and (elective) lymph nodes more concentrated but with fewer hospital visits (hypofractionation) * the tumor will get a higher dose * androgen deprivation therapy will be reduced as much al possible preventing side effects
Researchers will compare oncological outcome and toxicity.
Inclusion: Men (aged ≥18 years of age) diagnosed within 6 months before inclusion with high risk prostate cancer:; T3 based on digital rectal examination AND/OR; Grade >= 4 AND/OR; PSA >=20 ug/L; Indication for elective lymph node irradiation (based on current clinical guidelines) OR N1 on imaging (with a maximum of 4 suspect lymph nodes).
Exclusion: Prior pelvic radiotherapy; TransUrethral Resection of the Prostate (TURP) < 3 months ago; Prostatectomy or other primary treatment for prostate cancer (e.g. HIFU, cryotherapy, etc); inflammatory bowel disease; metastatic disease (M1); medical history of cancer other than basal cell carcinoma of the skin; contraindications to MRI; no visible lesion on MRI in prostate for boost; no PSMA-PET scan; PSA >50; unsuitable for SBRT or WPRT.